The pharmacogenomics of anti-platelet intervention (PAPI) study: Variation in platelet response to clopidogrel and aspirin
2015
Clopidogrel and aspirin are commonly prescribed anti-platelet medications indicated for patients
who have experienced, or are at risk for, ischemic cardiovascular events. The Pharmacogenomics
of Anti-Platelet Intervention (PAPI) Study was designed to characterize determinants of clopidogrel
and dual anti-platelet therapy (DAPT) response in a healthy cohort of Old Order Amish from
Lancaster, PA. Following a loading dose, clopidogrel was taken once a day for 7 days. One hour after the last dose of
clopidogrel, 325 mg of aspirin was given. Ex vivo platelet aggregometry was performed at baseline, post-clopidogrel, and
post-DAPT. Platelet aggregation measurements were significantly lower after both interventions for all agonists tested (p
2 ) of change in platelet aggregation was significant for most traits at
all time-points (range h 2 =0.14-0.57). Utilization of a standardized, short-term intervention provided a powerful approach
to investigate sources of variation in platelet aggregation response due to drug therapy. Further, this short-term intervention
approach may provide a useful paradigm for pharmacogenomics studies.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
22
References
8
Citations
NaN
KQI